178974-59-9

Basic information

• Product Name: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)
• Synonyms: Benzenemethanol, 2-fluoro-3-methoxy- (9CI);2-Fluoro-3-methoxyBenzylalcohol;2-Fluoro-3-(hydroxymethyl)anisole;(2-fluoro-3-Methoxyphenyl)Methanol
• CAS NO: 178974-59-9
• Molecular Formula: C₈H₉FO₂
• Molecular Weight: 156.1542632
• Product Categories: HALIDE
• Mol File: 178974-59-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 254.1°Cat760mmHg
• Flash Point: 123.9°C
• Appearance: /
• Density: 1.187g/cm³
• Vapor Pressure: 0.00913mmHg at 25°C
• Refractive Index: 1.51
• CAS DataBase Reference: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(178974-59-9)
• EPA Substance Registry System: Benzenemethanol, 2-fluoro-3-methoxy- (9CI)(178974-59-9)

Safety Data

• Hazardous Substances Data: 178974-59-9(Hazardous Substances Data)

Usage

General Description

Benzenemethanol, 2-fluoro-3-methoxy- (9CI) is a chemical compound with the molecular formula C8H9FO2. It is an aromatic alcohol with a 2-fluoro-3-methoxy substitution on the benzene ring. Benzenemethanol, 2-fluoro-3-methoxy- (9CI) is used in the field of organic chemistry and pharmaceutical research as a building block for the synthesis of various biologically active molecules and pharmaceuticals. It has potential applications in the development of new drugs and pharmaceutical products. Additionally, it is important to handle this compound with caution as it may have certain safety hazards associated with its use and handling.

InChI:InChI=1/C8H9FO2/c1-11-7-4-2-3-6(5-10)8(7)9/h2-4,10H,5H2,1H3

Upstream product

• 137654-20-7 2-fluoro-3-methoxybenzoic acid 
• 321-28-8 1-fluoro-2-methoxybenzene 
• 103438-88-6 2-fluoro-3-methoxybenzaldehyde 

Downstream Products

• 447463-56-1 1-(bromomethyl)-2-fluoro-3-methoxybenzene 
• 447463-13-0 (3-{4-[1-(2-fluoro-3-methoxy-benzyloxy)-ethyl]-2-methoxy-5-nitro-phenoxy}-propyl)-carbamic acid tert-butyl ester 
• 178974-63-5 1-(chloromethyl)-2-fluoro-3-methoxybenzene 
• 1143571-77-0 (2-fluoro-3-methoxyphenyl)methyl methanesulfonate 
• 672931-80-5 (2-fluoro-3-methoxyphenyl)acetonitrile 
• 1344028-80-3 N-{2-[(2-fluoro-3-methoxyphenyl)ethyl]}-2-methylpropanamide 
• 910400-77-0 2-(2-fluoro-3-methoxyphenyl)ethylamine 
• 1344029-93-1 5-fluoro-1-isopropyl-6-methoxy-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline 
• 863645-29-8 2-(2-fluoro-3-methoxyphenyl)acetic acid 
• 1060782-57-1 N-(2-fluoro-3-hydroxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1143571-78-1 N-(2-fluoro-3-methoxyphenyl)methylphthalimide 
• 1143571-71-4 2-fluoro-3-methoxybenzylamine hydrochloride 
• 1202182-61-3 N-(2-fluoro-3-methoxyphenyl)methyl-benzothiazole-6-carboxamide 
• 1202182-63-5 N-(3-ethoxy-2-fluorophenyl)methyl-benzothiazole-6-carboxamide 

Relevant articles and documents

Synthesis method of elagolix intermediate

The invention relates to a synthesis method of an elagolix intermediate. Specifically, the invention provides a synthesis method of an elagolix intermediate compound X and an elagolix intermediate compound I. According to the method, 2-fluoro-3-methoxy-phenylacetic acid is used as a raw material, and the steps of cyclization, hydrolysis, amino protection, condensation, Mitsunobu reaction and the like are carried out in sequence, so that the elagolix intermediate compound X and the elagolix intermediate compound I are obtained. The method has the advantages of cheap and easily available reagents, high conversion rate, simple operation and low process cost, and is suitable for industrialization.

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4- tetrahydroisoquinoline derivatives as novel antihypertensive agents

A series of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized and their bradycardic activities were evaluated in isolated guinea pig right atria. Structure-activity relationship studies revealed that the introduction of an appropriate substituent and its position on the 1,2,3,4-tetrahydroisoquinoline ring are essential for potent in vitro activity. Furthermore, the tether between the piperidyl moiety and the terminal aromatic ring is important for potent antihypertensive activity. Oral administration of 6-fluoro-1-isopropyl-2-{[1-(2-phenylethyl)piperidin-4-yl]carbonyl}-1,2,3, 4-tetrahydroisoquinoline (3b) to spontaneously hypertensive rats (SHR) elicited antihypertensive effects without inducing reflex tachycardia, which is often caused by traditional L-type Ca2+ channel blockers.